209 related articles for article (PubMed ID: 35926206)
1. Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.
Cockrum RH; Soo J; Ham SA; Cohen KS; Snow SG
Obstet Gynecol; 2022 Sep; 140(3):477-487. PubMed ID: 35926206
[TBL] [Abstract][Full Text] [Related]
2. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
3. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
Sangkomkamhang US; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
[TBL] [Abstract][Full Text] [Related]
4. Cyclical progestogens for heavy menstrual bleeding.
Bofill Rodriguez M; Lethaby A; Low C; Cameron IT
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD001016. PubMed ID: 31425626
[TBL] [Abstract][Full Text] [Related]
5. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
6. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
8. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.
Sangkomkamhang US; Lumbiganon P; Laopaiboon M; Mol BW
Cochrane Database Syst Rev; 2013 Feb; (2):CD008994. PubMed ID: 23450594
[TBL] [Abstract][Full Text] [Related]
9. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
Schink T; Princk C; Braitmaier M; Haug U
BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
[TBL] [Abstract][Full Text] [Related]
10. Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum.
Tepper NK; Jeng G; Curtis KM; Boutot ME; Boulet SL; Whiteman MK
Obstet Gynecol; 2019 Mar; 133(3):533-540. PubMed ID: 30741807
[TBL] [Abstract][Full Text] [Related]
11. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
12. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
13. Use of progestogens and the risk of intracranial meningioma: national case-control study.
Roland N; Neumann A; Hoisnard L; Duranteau L; Froelich S; Zureik M; Weill A
BMJ; 2024 Mar; 384():e078078. PubMed ID: 38537944
[TBL] [Abstract][Full Text] [Related]
14. Progestin-only contraception and thromboembolism: A systematic review.
Tepper NK; Whiteman MK; Marchbanks PA; James AH; Curtis KM
Contraception; 2016 Dec; 94(6):678-700. PubMed ID: 27153743
[TBL] [Abstract][Full Text] [Related]
15. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
16. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
17. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
Scarabin PY
Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359
[TBL] [Abstract][Full Text] [Related]
18. Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk.
Raine-Bennett T; Chandra M; Armstrong MA; Alexeeff S; Lo JC
Obstet Gynecol; 2019 Sep; 134(3):581-589. PubMed ID: 31403601
[TBL] [Abstract][Full Text] [Related]
19. Steroidal contraceptives and bone fractures in women: evidence from observational studies.
Lopez LM; Chen M; Mullins Long S; Curtis KM; Helmerhorst FM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009849. PubMed ID: 26195091
[TBL] [Abstract][Full Text] [Related]
20. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
